Allergy & Immunology

A novel CAR T cell therapy has shown encouraging results in children and adults with relapsed/refractory B-cell acute lymphoblastic leukaemia.

Each year, up to 138,000 people die and around 400,000 more are left permanently disabled from snakebites.

Researchers have explored the potential of intense pulsed light therapy as a supplementary treatment for refractory SAC.

The analysis demonstrated significant reductions in HAE attacks among adolescent patients.

Researchers developed a new evolutionary framework centred on immune robustness, the ability to fight infection while limiting damage.

A recent randomised clinical trial sought to determine whether high-dose aspirin remains necessary during acute-stage KD treatment.

The RILECSU phase 2 clinical trial has introduced a potential new option: rilzabrutinib.

During the immunosuppressive phase, researchers identified a marked decline in monocyte function and maturation.